Mural Oncology is halting development of its lead IL-2 therapy and enacting major layoffs after its second trial failure this ...

Mural Oncology (MURA) announced that following review of data from its phase 2 ARTISTRY-6 trial in melanoma and previously announced results ...

The writing is on the wall at Mural Oncology. Responding to clinical data, the biotech is laying off 90% of its employees and ...

Mural Oncology stock skyrockets after it begins exploring strategic alternatives to maximize shareholder value after the failure of two cancer studies for nemvaleukin alfa.

Mural Oncology plc said on Tuesday it would stop clinical development of its lead cancer treatment, nemvaleukin, and look ...

After disappointing trial results for cancer treatments, Mural Oncology announced Wednesday it is cutting 90% of its workforce.

Mural Oncology plc (NASDAQ:MURA), a biotech company specializing in immuno-oncology, announced it will cease all clinical development of its drug candidate nemvaleukin alfa, following a review of ...

Real-time index price for TSX 60 Index (TXSX), along with buy or sell indicators, analysis, charts, historical performance, ...

US biotech Mural Oncology has halted all development of its lead candidate, nemvaleukin alfa, after the engineered cytokine ...

WALTHAM, Mass. - Mural Oncology plc (NASDAQ:MURA), a biotech company specializing in immuno-oncology, announced it will cease all clinical development of its drug candidate nemvaleukin alfa, following ...

Shares of Mural Oncology plc (NASDAQ: MURA) are soaring Monday following the company's announcement that it will discontinue clinical development of its lead drug candidate Nemvaleukin and begin ...

Mural on Tuesday said it is ending all clinical development of its proposed nemvaleukin alfa cancer treatment and focusing on maximizing shareholder value. The Dublin-based company said it plans to ...